Evaluation Studies of the DEN-2/S-1 Vaccine.
Annual rept. Aug 80-Jul 81,
PUERTO RICO UNIV SAN JUAN
Pagination or Media Count:
A dengue-2 live virus vaccine was tested in monkeys immune to heterologous dengue serotypes to determine if, as with wild DEN-2 virus, antibody-enhanced viraemia and seroconversion would occur. A low dose of 900 plaque-forming units PFU of the DEN-2S-1 vaccine virus was inoculated subcutaneously into rhesus monkeys six months after they had received wild Den-1, Den-2 or Den-3 viruses, and into non-immune monkeys. As previously reported for non-immune monkeys, these was little, if any, detectable vaccine viraemia in any of the group of monkeys. There was no difference in seroconversion between the dengue heteorologous immune 36 and non immune 13 monkeys. These data indicated that 1 the vaccine virus may differ from the parent virus in the ability to complex with heterologous antibody and thus, in the ability to infect Fc receptor bearing cells in monkeys 2 1000 PFU of vaccine virus is approximately the 50 infectious dose in monkeys as measured by seroconversion.
- Medicine and Medical Research